Ahire C, Nyul-Toth A, DelFavero J, et al. Aging cell 2023;22(7):e13832.
The test records were read three times by AI and checked by code. No person has reviewed them yet. How records are made
| Setting | Value | Paper’s words |
|---|---|---|
| Walkway size, run duration criterion, number of runs, camera frame rate |
| “using our previously reported protocol (Ungvari et al., 2017)” |
| Apparatus | ||
| CatWalk | Noldus Information Technology Inc. | “we tested the experimental groups of mice using an automated computer assisted method (CatWalk; Noldus Information Technology Inc.)” |
| Methods cited to other work | ||
| CatWalk gait analysis protocol (walkway, run criteria, number of runs, recording settings) | Ungvari et al., 2017 | |
| Setting | Value | Paper’s words |
|---|---|---|
| Muscle strength of mouse forelimbs | forelimbs | “the grip strength test was used to measure the maximal muscle strength of mouse forelimbs” |
| Setting | Value | Paper’s words |
|---|---|---|
| Trial duration, number of trials, water temperature, pool size, platform size, platform depth below the surface |
| “following our published protocols (Yabluchanskiy et al., 2020)” |
| Apparatus | ||
| Radial arms water maze | “spatial memory and long term memory were tested by assessing performance in the radial arms water maze at 6 months post‐chemotherapy” | |
| Methods cited to other work | ||
| Radial arms water maze testing protocol (procedure and apparatus settings) | Yabluchanskiy et al., 2020 | |
| Setting | Value | Paper’s words |
|---|---|---|
| Not in the Methods | Rod speed, trial duration, number of trials | |
| Other settings in the paper | ||
| Lane | four‐lane | “automated four‐lane rotarod tool” |
| Apparatus | ||
| Automated four‐lane rotarod tool | “Motor coordination was assessed using an automated four‐lane rotarod tool.” | |
| Setting | Value | Paper’s words |
|---|---|---|
| Session duration, arm size |
| “according to our published protocol (Csiszar et al., 2013)” |
| Other settings in the paper | ||
| Delayed alternation task | two‐trial | “Y‐maze two‐trial delayed alternation task” |
| Apparatus | ||
| Y‐maze | “Hippocampal‐dependent contextual memory was tested with the Y‐maze two‐trial delayed alternation task” | |
| Methods cited to other work | ||
| Y‐maze two‐trial delayed alternation procedure (all settings, including session duration and arm size) | Csiszar et al., 2013 | |
A person went through this paper’s whole Methods section, beyond the behavioral tests, and confirmed these 141 facts against the text. No person has checked the test records above.
| Item | Value | Paper’s words |
|---|---|---|
| Main experimentBlinding | The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer | “The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer.” |
| Main experimentObjective | To identify and eliminate senescent cells | “To identify and eliminate senescent cells, we used a novel transgenic mouse model (p16‐3MR mice; Yabluchanskiy et al., 2020)” |
| Main experimentRandomization | PTX treated mice were assigned randomly to three groups | “PTX treated mice were assigned randomly to three groups.” |
| Animal protocol approvalApproval | Institutional Animal Care and Use Committee of the OUHSC | “All animal protocols were approved by the Institutional Animal Care and Use Committee of the OUHSC.” |
| Item | Value | Paper’s words |
|---|---|---|
| p16-3MR miceSex | male | “Three‐month‐old male p16‐3MR mice” |
| p16-3MR miceSpecies | mouse | “we used a novel transgenic mouse model (p16‐3MR mice; Yabluchanskiy et al., 2020)” |
| Experiment subjectsSex | male | “Three‐month‐old male p16‐3MR mice” |
| Experiment subjectsSpecies | mouse | “Three‐month‐old male p16‐3MR mice” |
| Experiment subjectsStrain | p16‐3MR | “p16‐3MR mice” |
| PTX groupN allocated | 150 | “PTX (5 mg/kg/day, i.p., n = 150)” |
| vehicle groupN allocated | 50 | “vehicle (DMSO + saline, n = 50)” |
| post-PTX vehicle groupLabel | vehicle controls | “The third group served as vehicle controls.” |
| Item | Value | Paper’s words |
|---|---|---|
| PTXName | PTX | “PTX (5 mg/kg/day, i.p., n = 150)” |
| PTX administrationDose | 5 mg/kg/day | “PTX (5 mg/kg/day, i.p., n = 150)” |
| PTX administrationRoute | i.p. | “PTX (5 mg/kg/day, i.p., n = 150)” |
| PTX administrationSchedule | 2 cycles (5 days/cycle) with a 7‐day interval between cycles | “in 2 cycles (5 days/cycle) with a 7‐day interval between cycles” |
| vehicle (DMSO + saline)Name | DMSO + saline | “vehicle (DMSO + saline, n = 50)” |
| ABT263Catalog number | C‐1009 | “ABT263 (Navitoclax, Chemgood, C‐1009” |
| ABT263Manufacturer | Chemgood | “ABT263 (Navitoclax, Chemgood, C‐1009” |
| ABT263Name | ABT263 (Navitoclax) | “ABT263 (Navitoclax, Chemgood, C‐1009, i.p., 1.5 mg/kg/daily in DMSO/saline)” |
| ABT263 administrationDose | 1.5 mg/kg/daily | “i.p., 1.5 mg/kg/daily in DMSO/saline” |
| ABT263 administrationRoute | i.p. | “i.p., 1.5 mg/kg/daily in DMSO/saline” |
| ABT263 administrationSchedule | 5 days and 2 cycles with a 2 week interval between cycles | “for 5 days and 2 cycles with a 2 week interval between cycles” |
| ABT263 administrationVehicle | DMSO/saline | “in DMSO/saline” |
| ganciclovir (GCV)Catalog number | RG001 | “ganciclovir (GCV [TSZCHEM, RG001, >99%]” |
| ganciclovir (GCV)Manufacturer | TSZCHEM | “ganciclovir (GCV [TSZCHEM, RG001, >99%]” |
| ganciclovir (GCV)Name | ganciclovir (GCV) | “ganciclovir (GCV [TSZCHEM, RG001, >99%]; i.p. 25 mg/kg/daily)” |
| ganciclovir administrationDose | 25 mg/kg/daily | “i.p. 25 mg/kg/daily” |
| ganciclovir administrationRoute | i.p. | “i.p. 25 mg/kg/daily” |
| GCV administrationSchedule | 5 days and 2 cycles with a 2 week interval between cycles | “for 5 days and 2 cycles with a 2 week interval between cycles” |
| CatWalkManufacturer | Noldus Information Technology Inc. | “CatWalk; Noldus Information Technology Inc.” |
| CatWalkName | CatWalk | “an automated computer assisted method (CatWalk; Noldus Information Technology Inc.)” |
| isofluraneName | isoflurane | “mice in each group were anesthetized with isoflurane (2% induction and 1% maintenance)” |
| isoflurane anesthesiaDose | 2% induction | “isoflurane (2% induction and 1% maintenance)” |
| isoflurane inductionDose | 2% | “isoflurane (2% induction” |
| isoflurane maintenanceDose | 1% | “1% maintenance” |
| L-NAME administrationParameter | after administrating the nitric oxide synthase inhibitor Nω‐Nitro‐L‐arginine methyl ester (L‐NAME) | “after administrating the nitric oxide synthase inhibitor Nω‐Nitro‐L‐arginine methyl ester (L‐NAME)” |
| L-NAMEName | Nω‐Nitro‐L‐arginine methyl ester (L‐NAME) | “nitric oxide synthase inhibitor Nω‐Nitro‐L‐arginine methyl ester (L‐NAME)” |
| paraformaldehydeName | paraformaldehyde | “immersion fixed in 4% paraformaldehyde for 24 hours” |
| RFP-Booster (AlexaFluor-488)Catalog number | US‐QUO201590 | “US‐QUO201590” |
| RFP-Booster (AlexaFluor-488)Manufacturer | Chromotek | “Chromotek” |
| RFP-Booster (AlexaFluor-488)Name | RFP‐Booster (AlexaFluor‐488) | “Fixed cells were stained with the RFP‐Booster (AlexaFluor‐488, 1:1000; Chromotek; US‐QUO201590, 0.5 gm/L)” |
| RFP-Booster stainingConcentration | 0.5 gm/L | “0.5 gm/L” |
| RFP-Booster stainingParameter | 1:1000 | “1:1000” |
| RFP-Booster stainingVolume | 1:1000 | “1:1000” |
| MACS bufferManufacturer | Miltenyi Biotech | “MACS buffer (Miltenyi Biotech)” |
| MACS bufferName | MACS buffer | “resuspended in MACS buffer (Miltenyi Biotech)” |
| antibody against CD31Name | antibody directed against the endothelium‐specific surface marker CD31 | “labelled with an antibody directed against the endothelium‐specific surface marker CD31” |
| Guava EasyCyte BGR HT Flow CytometerManufacturer | Luminex | “Guava® EasyCyte™ BGR HT Flow Cytometer (Luminex)” |
| Guava EasyCyte BGR HT Flow CytometerName | Guava® EasyCyte™ BGR HT Flow Cytometer | “using a Guava® EasyCyte™ BGR HT Flow Cytometer (Luminex)” |
| WOLF Cell SorterManufacturer | NanoCellect | “WOLF Cell Sorter™ (NanoCellect)” |
| WOLF Cell SorterName | WOLF Cell Sorter™ | “WOLF Cell Sorter™ (NanoCellect)” |
| PTX (for cell culture)Name | PTX | “Human CMVECs were treated with vehicle (DMSO in media) or PTX (Ramanathan et al., 2005) for 10 days” |
| vehicle (DMSO in media)Name | DMSO in media | “vehicle (DMSO in media)” |
| IBA-1 antibodyManufacturer | Fijifilm | “Fijifilm” |
| IBA-1 antibodyName | rabbit anti‐mouse Iba‐I antibody | “immunolabeled for IBA‐1 (rabbit anti‐mouse Iba‐I antibody; 1:200, Fijifilm; overnight at 4°C)” |
| IBA-1 antibody additionParameter | 1:200 | “1:200” |
| IBA-1 antibody incubationConcentration | 1:200 | “1:200” |
| endomucin antibodyManufacturer | Invitrogen | “Invitrogen” |
| endomucin antibodyName | rat monoclonal anti‐mouse endomucin antibody | “the endothelial marker endomucin (rat monoclonal anti‐mouse endomucin antibody; 1:50, Invitrogen; overnight at 4°C)” |
| rat monoclonal anti-mouse endomucin antibodyManufacturer | Invitrogen | “Invitrogen” |
| rat monoclonal anti-mouse endomucin antibodyName | rat monoclonal anti‐mouse endomucin antibody | “rat monoclonal anti‐mouse endomucin antibody; 1:50, Invitrogen” |
| endomucin antibody additionParameter | 1:50 | “1:50” |
| endomucin antibody incubationConcentration | 1:50 | “1:50” |
| Leica SP8 MP confocal laser scanning microscopeName | Leica SP8 MP confocal laser scanning microscope | “Confocal images were obtained using Leica SP8 MP confocal laser scanning microscope.” |
| Item | Value | Paper’s words |
|---|---|---|
| whole brainsName | whole brains | “Whole brains were collected for FACS analysis and transcriptomics.” |
| acute brain slicesName | acute brain slices | “Acute brain slices were collected for LTP measurements.” |
| half brainsName | half brains | “Half brains were immersion fixed in 4% paraformaldehyde for 24 hours” |
| human CMVECsName | human cerebromicrovascular endothelial cells (CMVECs) | “cultured human cerebromicrovascular endothelial cells (CMVECs)” |
| Item | Value | Paper’s words |
|---|---|---|
| PTX administrationDuration | 2 cycles (5 days/cycle) with a 7‐day interval between cycles | “in 2 cycles (5 days/cycle) with a 7‐day interval between cycles” |
| Recovery after PTXAction | Mice were left to recover for 2 weeks in the original environment. | “Mice were left to recover for 2 weeks in the original environment.” |
| Recovery after PTXDuration | 2 weeks | “Mice were left to recover for 2 weeks in the original environment.” |
| Random assignment after PTXAction | PTX treated mice were assigned randomly to three groups | “PTX treated mice were assigned randomly to three groups.” |
| Euthanize mice for tissue collectionAction | then were euthanized for tissue collection | “then were euthanized for tissue collection” |
| Tissue collection after testingAction | euthanized for tissue collection | “then were euthanized for tissue collection” |
| Radial arms water maze testingExternal protocol | Yabluchanskiy et al., 2020 | “following our published protocols (Yabluchanskiy et al., 2020)” |
| Radial arms water maze testingAction | spatial memory and long term memory were tested by assessing performance in the radial arms water maze | “spatial memory and long term memory were tested by assessing performance in the radial arms water maze” |
| Y-maze spatial memory testingAction | Hippocampal‐dependent contextual memory was tested with the Y‐maze two‐trial delayed alternation task | “Hippocampal‐dependent contextual memory was tested with the Y‐maze two‐trial delayed alternation task” |
| Y-maze spatial memory testingExternal protocol | Csiszar et al., 2013 | “according to our published protocol (Csiszar et al., 2013)” |
| Grip strength testAction | the grip strength test was used to measure the maximal muscle strength of mouse forelimbs | “the grip strength test was used to measure the maximal muscle strength of mouse forelimbs” |
| Rotarod testAction | Motor coordination was assessed using an automated four‐lane rotarod tool | “Motor coordination was assessed using an automated four‐lane rotarod tool” |
| CatWalk gait analysisAction | we tested the experimental groups of mice using an automated computer assisted method (CatWalk; Noldus Information Technology Inc.) | “we tested the experimental groups of mice using an automated computer assisted method (CatWalk; Noldus Information Technology Inc.)” |
| Gait analysisExternal protocol | Ungvari et al., 2017 | “using our previously reported protocol (Ungvari et al., 2017)” |
| Chronic cranial windowAction | mice were equipped with a chronic cranial window | “mice were equipped with a chronic cranial window” |
| Intravital two-photon microscopyAction | intravital two‐photon microscopy‐based and optical coherence tomography (OCT) based imaging methods were used | “intravital two‐photon microscopy‐based and optical coherence tomography (OCT) based imaging methods were used” |
| Intravital two-photon microscopyExternal protocol | Nyul‐Toth et al., 2021 | “as previously described (Nyul‐Toth et al., 2021)” |
| Assessment of neurovascular coupling responsesAction | NVC responses were assessed | “NVC responses were assessed as described previously” |
| Assessment of neurovascular coupling responsesExternal protocol | Tarantini, Balasubramanian, et al., 2021; Tarantini et al., 2018, 2021 | “as described previously (Tarantini, Balasubramanian, et al., 2021; Tarantini et al., 2018, 2021)” |
| NVC response assessmentAction | NVC responses were assessed | “NVC responses were assessed as described previously (Tarantini, Balasubramanian, et al., 2021; Tarantini et al., 2018, 2021)” |
| NVC response assessmentExternal protocol | Tarantini, Balasubramanian, et al., 2021; Tarantini et al., 2018, 2021 | “NVC responses were assessed as described previously (Tarantini, Balasubramanian, et al., 2021; Tarantini et al., 2018, 2021)” |
| Anesthesia and ventilationAction | anesthetized with isoflurane (2% induction and 1% maintenance), endotracheally intubated, and ventilated | “anesthetized with isoflurane (2% induction and 1% maintenance), endotracheally intubated, and ventilated” |
| Endotracheal intubation and ventilationAction | endotracheally intubated, and ventilated | “endotracheally intubated, and ventilated” |
| Skull thinningAction | The skull was thinned | “The skull was thinned” |
| CBF measurementAction | changes in cerebral blood flow (CBF) were assessed above the left somatosensory whisker barrel cortex in response to mechanical stimulation of the right whiskers | “changes in cerebral blood flow (CBF) were assessed above the left somatosensory whisker barrel cortex in response to mechanical stimulation of the right whiskers” |
| Whisker stimulationAction | mechanical stimulation of the right whiskers | “mechanical stimulation of the right whiskers” |
| L-NAME administrationAction | CBF responses to whisker stimulation were repeated after administrating the nitric oxide synthase inhibitor Nω‐Nitro‐L‐arginine methyl ester (L‐NAME) | “CBF responses to whisker stimulation were repeated after administrating the nitric oxide synthase inhibitor Nω‐Nitro‐L‐arginine methyl ester (L‐NAME)” |
| Perfusion and brain collectionAction | the animals were transcardially perfused with ice‐cold PBS and decapitated. The brains were immediately removed and samples were collected for subsequent studies | “the animals were transcardially perfused with ice‐cold PBS and decapitated. The brains were immediately removed and samples were collected for subsequent studies” |
| Fixation in paraformaldehydeAction | immersion fixed in 4% paraformaldehyde for 24 hours | “immersion fixed in 4% paraformaldehyde for 24 hours” |
| Fixation in paraformaldehydeDuration | 24 hours | “immersion fixed in 4% paraformaldehyde for 24 hours” |
| Sucrose gradient transfer and embeddingAction | transferred to sucrose gradients and embedded and cut for immunohistochemistry | “transferred to sucrose gradients and embedded and cut for immunohistochemistry” |
| Transfer to sucrose gradientsAction | transferred to sucrose gradients | “transferred to sucrose gradients” |
| Embedding and sectioning for immunohistochemistryAction | embedded and cut for immunohistochemistry | “embedded and cut for immunohistochemistry” |
| Electrophysiological recordingsAction | extracellular recordings were performed from acute hippocampal slices obtained from a separate cohort of control and PTX‐treated animals | “extracellular recordings were performed from acute hippocampal slices obtained from a separate cohort of control and PTX‐treated animals” |
| Electrophysiological studies for LTPAction | extracellular recordings were performed from acute hippocampal slices obtained from a separate cohort of control and PTX‐treated animals | “extracellular recordings were performed from acute hippocampal slices obtained from a separate cohort of control and PTX‐treated animals” |
| Electrophysiological studies (LTP)External protocol | Tucsek et al., 2017 | “as described (Tucsek et al., 2017)” |
| Senescent cell burden analysisExternal protocol | Yabluchanskiy et al., 2020 | “using our published protocols (Yabluchanskiy et al., 2020)” |
| Single-cell suspension preparationAction | single‐cell suspensions were prepared | “single‐cell suspensions were prepared” |
| RFP-Booster incubationDuration | 30 min | “for 30 min” |
| Centrifugation after RFP-BoosterDuration | 10 min | “centrifuged (300 × g, 10 min)” |
| Centrifugation after RFP-BoosterParameter | 300 × g, 10 min | “centrifuged (300 × g, 10 min)” |
| FACS sortingAction | Fluorescent activated cell sorting (FACS) with the low‐pressure WOLF Cell Sorter™ (NanoCellect) was used to obtain a cell suspension enriched in brain senescent cells | “Fluorescent activated cell sorting (FACS) with the low‐pressure WOLF Cell Sorter™ (NanoCellect) was used to obtain a cell suspension enriched in brain senescent cells” |
| FACS sorting of senescent cellsAction | Fluorescent activated cell sorting (FACS) with the low‐pressure WOLF Cell Sorter™ (NanoCellect) was used to obtain a cell suspension enriched in brain senescent cells | “Fluorescent activated cell sorting (FACS) with the low‐pressure WOLF Cell Sorter™ (NanoCellect) was used to obtain a cell suspension enriched in brain senescent cells” |
| SA-β-gal activity in CMVECsAction | we measured SA‐β‐gal activity in PTX‐treated cultured human cerebromicrovascular endothelial cells (CMVECs) | “we measured SA‐β‐gal activity in PTX‐treated cultured human cerebromicrovascular endothelial cells (CMVECs)” |
| SA-β-gal quantificationAction | The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer. | “The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer.” |
| SA-β-gal quantificationParameter | The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer. | “The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer.” |
| β-galactosidase-positive cell countingAction | The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer | “The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated by a naïve observer” |
| Single-cell transcriptomicsAction | a single‐cell transcriptomics‐based method was also used | “a single‐cell transcriptomics‐based method was also used” |
| Single-cell transcriptomicsExternal protocol | Kiss et al., 2020 | “as described (Kiss et al., 2020)” |
| Gel bead-in-emulsion droplet sequencingAction | We used a gel bead‐in‐emulsion‐based droplet sequencing method | “We used a gel bead‐in‐emulsion‐based droplet sequencing method” |
| Cell cluster identificationAction | Cell clusters were identified by the expression of known, previously validated canonical cell type markers | “Cell clusters were identified by the expression of known, previously validated canonical cell type markers” |
| Gene set enrichment analysisAction | The set of senescence‐related core genes used for gene set enrichment analysis is given in Table S2 | “The set of senescence‐related core genes used for gene set enrichment analysis is given in Table S2” |
| Endothelial cell sub-clusteringAction | endothelial cells were divided into three sub‐clusters: endothelial cells form arteries, veins and capillaries using canonical marker genes (Table S3) | “endothelial cells were divided into three sub‐clusters: endothelial cells form arteries, veins and capillaries using canonical marker genes (Table S3)” |
| Spatial transcriptomicsAction | Spatial transcriptomics (ST) was used to assess spatial distribution of senescent cells in brains of PTX‐treated mice | “Spatial transcriptomics (ST) was used to assess spatial distribution of senescent cells in brains of PTX‐treated mice” |
| Spatial transcriptomicsExternal protocol | Kiss et al., 2022 | “as previously described (Kiss et al., 2022)” |
| Spatially resolved whole transcriptome mRNA expressionAction | Spatially resolved whole transcriptome mRNA expression was analyzed in sections of brains | “Spatially resolved whole transcriptome mRNA expression was analyzed in sections of brains” |
| Microdomain mappingAction | Microdomains containing senescent cells were identified on the basis of their senescence‐related gene expression profiles and were mapped to different anatomical brain regions | “Microdomains containing senescent cells were identified on the basis of their senescence‐related gene expression profiles and were mapped to different anatomical brain regions” |
| Perfusion-fixation and sectioningAction | Brains were perfusion‐fixed and frozen OCT‐embedded sagittal sections (35 μm) were cut | “Brains were perfusion‐fixed and frozen OCT‐embedded sagittal sections (35 μm) were cut” |
| IBA-1 immunolabelingAction | Sections were immunolabeled for IBA‐1 (rabbit anti‐mouse Iba‐I antibody; 1:200, Fijifilm; overnight at 4°C) | “Sections were immunolabeled for IBA‐1 (rabbit anti‐mouse Iba‐I antibody; 1:200, Fijifilm; overnight at 4°C)” |
| Endomucin immunolabelingAction | the endothelial marker endomucin (rat monoclonal anti‐mouse endomucin antibody; 1:50, Invitrogen; overnight at 4°C) | “the endothelial marker endomucin (rat monoclonal anti‐mouse endomucin antibody; 1:50, Invitrogen; overnight at 4°C)” |
| Confocal imagingAction | Confocal images were obtained using Leica SP8 MP confocal laser scanning microscope | “Confocal images were obtained using Leica SP8 MP confocal laser scanning microscope.” |
| IBA-1 intensity analysisAction | The relative staining intensity for IBA‐1 positive perivascular microglia per region of interest was assessed | “The relative staining intensity for IBA‐1 positive perivascular microglia per region of interest was assessed” |
| IBA-1 intensity quantificationAction | The relative staining intensity for IBA‐1 positive perivascular microglia per region of interest was assessed | “The relative staining intensity for IBA‐1 positive perivascular microglia per region of interest was assessed.” |
| Item | Value | Paper’s words |
|---|---|---|
| Grip strengthMeasure | Grip strength | “the grip strength test was used to measure the maximal muscle strength of mouse forelimbs” |
| Ratio of RFP+/CD31+ senescent endothelial cellsMeasure | Ratio of RFP+/CD31+ senescent endothelial cells as a percentage of all CD31+ endothelial cells | “the ratio of RFP+/CD31+ senescent endothelial cells as a percentage of all CD31+ endothelial cells were determined” |
| SA-β-gal activity in CMVECsMeasure | SA‐β‐gal activity in PTX‐treated cultured human cerebromicrovascular endothelial cells (CMVECs) | “we measured SA‐β‐gal activity in PTX‐treated cultured human cerebromicrovascular endothelial cells (CMVECs)” |
| Percentage of β‐galactosidase‐positive cellsMeasure | Percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) | “The percentage of β‐galactosidase‐positive cells (blue cytoplasmic staining) was calculated” |
| Relative staining intensity for IBA‐1 positive perivascular microgliaMeasure | Relative staining intensity for IBA‐1 positive perivascular microglia per region of interest | “The relative staining intensity for IBA‐1 positive perivascular microglia per region of interest was assessed.” |
| Statistical analysisAlpha | p < 0.05 | “Differences were considered significant at p < 0.05.” |
| Statistical analysisSoftware refs | GraphPad Prism 7.0 | “using GraphPad Prism 7.0, as appropriate.” |
| Statistical analysisTest | unpaired t test, one‐way or two‐way ANOVA with Fisher LSD post hoc test | “statistical analyses were carried out by unpaired t test, one‐way or two‐way ANOVA with Fisher LSD post hoc test” |
| Statistical analysisUncertainty | means ± standard error of mean (SEM) | “Data are presented as means ± standard error of mean (SEM)” |